Clinical concepts for cabazitaxel in the management of metastatic castration‐resistant prostate cancer

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel

Cabazitaxel: a new drug for metastatic prostate cancer.

I n Western countries, prostate cancer is the most common malignancy in men and ranks third in mortality. In 2010, an estimated 217 730 new cases are anticipated in the United States, and about 32 050 men are expected to die from the disease. Until 2004, numerous clinical trials in men with metastatic castration-resistant prostate cancer (mCRPC) failed to demonstrate any significant change in o...

Cabazitaxel in the Management of Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel-based Chemotherapy

Docetaxel is the guideline-recommended first-line chemotherapy in men with castration-resistant prostate cancer (CRPC). Despite its proven survival benefit, however, all patients will progress after a mean interval of six to eight months. Recently, the FDA approved cabazitaxel and abiraterone acetate as effective second-line treatment options in this clinical scenario. By comparison with mitoxa...

study of cohesive devices in the textbook of english for the students of apsychology by rastegarpour

this study investigates the cohesive devices used in the textbook of english for the students of psychology. the research questions and hypotheses in the present study are based on what frequency and distribution of grammatical and lexical cohesive devices are. then, to answer the questions all grammatical and lexical cohesive devices in reading comprehension passages from 6 units of 21units th...

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations

Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel. With the advent of new antiandrogen therapies, immune-based treatments, and radioactive-targeted therapy, there are now multiple effective and approved agents for this disease state. The optimal sequencing of these agents is unclear as ther...